Vir Biotechnology (VIR) appoints Timothy Coughlin as director and Audit Committee chair
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vir Biotechnology, Inc. announced that its Board of Directors increased in size from seven to eight members and appointed Timothy Coughlin, CPA, as a new Class III director effective June 9, 2026. He will serve on the Board until the company’s 2028 annual meeting of stockholders.
Coughlin was also appointed as Chair of the Audit Committee, giving him a key oversight role in the company’s financial reporting. He was not selected pursuant to any arrangement with another person, and the company reports no related party transactions requiring disclosure.
As a non-employee director, Coughlin will receive standard cash and equity compensation under Vir’s non-employee director compensation policy. On his appointment date, he received stock option and restricted stock unit awards under the company’s 2019 Equity Incentive Plan, and he entered into Vir’s standard indemnity agreement for directors.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board size: 8 members
Director class term: Until 2028 annual meeting
Appointment date: June 9, 2026
+1 more
4 metrics
Board size
8 members
Increased from seven to eight on June 9, 2026
Director class term
Until 2028 annual meeting
Class III director term for Timothy Coughlin
Appointment date
June 9, 2026
Effective date of Coughlin’s board and audit chair roles
Form reference
Form S-1 Exhibit 10.1
Standard indemnity agreement previously filed
Key Terms
Class III director, Audit Committee, non-employee director, 2019 Equity Incentive Plan, +1 more
5 terms
Class III director financial
"serve on the Board as a Class III director until the Company’s 2028 annual meeting"
A Class III director is a board member placed in one of the numbered groups used by companies with a staggered (or “classified”) board; that director’s seat typically comes up for election in the third year of a three-year rotation. For investors this matters because staggered terms create continuity but also make it harder to replace the whole board quickly, affecting shareholder influence, takeover dynamics and how fast new strategy or accountability can be implemented — like replacing only some players on a sports team each season instead of the whole roster at once.
Audit Committee financial
"the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
non-employee director financial
"As a non-employee director, Mr. Coughlin will receive the standard cash and equity compensation"
2019 Equity Incentive Plan financial
"granted stock option and restricted stock unit awards under the Company’s 2019 Equity Incentive Plan"
indemnity agreement financial
"the Company has entered into its standard form of indemnity agreement with Mr. Coughlin"
FAQ
What board change did Vir Biotechnology (VIR) disclose in this 8-K?
Vir Biotechnology expanded its Board of Directors from seven to eight members and appointed Timothy Coughlin, CPA, as a Class III director, effective June 9, 2026, to serve until the company’s 2028 annual meeting of stockholders.
What role will Timothy Coughlin hold at Vir Biotechnology (VIR)?
Timothy Coughlin will serve as a Class III director and Chair of the Audit Committee. This places him in a lead role overseeing Vir Biotechnology’s financial reporting and audit processes as part of the Board’s governance structure.
How will Vir Biotechnology (VIR) compensate new director Timothy Coughlin?
As a non-employee director, Timothy Coughlin will receive Vir Biotechnology’s standard cash and equity compensation. On appointment, he was granted stock option and restricted stock unit awards under the 2019 Equity Incentive Plan, subject to the policy’s vesting and other terms.
What indemnification protections does Vir Biotechnology (VIR) provide to Timothy Coughlin?
In addition to indemnification under its Bylaws, Vir Biotechnology entered into its standard form of indemnity agreement with Timothy Coughlin. This agreement is the same form previously filed as Exhibit 10.1 to the company’s Form S-1 registration statement.
What equity plan is referenced for Timothy Coughlin’s awards at Vir Biotechnology (VIR)?
Timothy Coughlin’s stock option and restricted stock unit awards were granted under Vir Biotechnology’s 2019 Equity Incentive Plan, pursuant to the automatic grant program described in the company’s non-employee director compensation policy.